Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus in Patients

Clinical Trial Analyzing the Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02154607

Enrollment

263

Registered

2014-06-03

Start date

2004-01-31

Completion date

2013-12-31

Last updated

2014-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus

Keywords

oral lichen planus, recurrence, Treatment, cancer, Primary disease Management

Brief summary

Oral Lichen Planus (OLP) is a common condition with its erosive variant occasionally presenting a management challenge to the clinician. In addition it can have debilitating consequences on the patients' quality of life. The malignant transformation of OLP has been well documented. The aims of this work were to measure the number of patients developing malignant transformationof OLP to squamous cell carcinoma (SCC) comparing patients undergoing traditional symptomatic treatments with those patients that were treated by CO2 laser from 2004 - 2011. Outcome measures were rated by incisional biopsy (histology Report).

Interventions

DEVICECO2-Laser Treatment

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Oral lichen planus * Histological confirmation of diagnosis * Patient willing for treatment

Exclusion criteria

* Patient just does not want to participate as control/study group

Design outcomes

Primary

Measure	Time frame
stable disease of OLP (clinical observation)	1 year

Secondary

Measure	Time frame
Development of oral cancer (histological report after incisional biopsy)	3 years

Other

Measure	Time frame
Development of reccurrence of OLP (clinical observation)	3 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026